Open AccessANALYSIS OF PROTEIN EXPRESSION OF PD-L1 IN MALIGNANT PLEURAL MESOTHELIOMA
Author(s) -
T.D. Karpenko,
Н. А. Козлов,
L. N. Lubchenko,
L E Rotobel'skaya,
С. Г. Багрова,
В. М. Сафронова,
К. К. Лактионов,
М. Б. Бычков
Publication year - 2018
Publication title -
rossijskij onkologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2412-9119
pISSN - 1028-9984
DOI - 10.18821/1028-9984-2018-23-1-4-9
Subject(s) - immunotherapy , immune system , pd l1 , mesothelioma , immune checkpoint , medicine , cancer research , immunology , oncology , pathology
Malignant pleural mesothelioma is associated with poor prognosis and resistance to chemotherapy. This gives reason to search for as well new effective methods of treatment as predictive factors. Programmed cell death receptor PD-1 and its ligands PD-L1 and PD-L2 are the representatives of the system of the «immunologic checkpoint» whose main function is the regulation and modulation of immune response, the decrease of the immune cell damage in organs and tissues and also prevention running of an autoimmune process. Tumor cells are able to use a PD-1/PD-L1-signaling pathway to evade the immune system. The assessment of the level of expression of PD-L1 is regarded as a prognostic marker of the life expectancy, but also as a predictor of response to anti-PD-1/PD-L1 immunotherapy.